Cite
HARVARD Citation
Bromberg, J. et al. (2019). Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet oncology. 20 (2), pp. 216-228. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bromberg, J. et al. (2019). Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet oncology. 20 (2), pp. 216-228. [Online].